Carbamazepine (All indications)

Hypospadias

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9653
R34360		 Bànhidy (Carbamazepine), 2011 Hypospadias throughout pregnancy case control unexposed, sick Adjustment: No Matched 0.33 [0.03;3.78] C 1/11   3/13 4 11
ref
S9664
R34411		 Jentink (Carbamazepine), 2010 Hypospadias 1st trimester case control unexposed (general population or NOS) Adjustment: Yes 0.70 [0.30;1.60] 6/-   -/- - -
ref
Total 2 studies 0.65 [0.29;1.43] 4 11
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bànhidy (Carbamazepine), 2011Bànhidy, 2011 1 0.33[0.03; 3.78]41111%ROB confusion: criticalROB selection: criticalROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate Jentink (Carbamazepine), 2010Jentink, 2010 2 0.70[0.30; 1.60]--89%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 0.65[0.29; 1.43]4110.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Carbamazepine; 2: Carbamazepine;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0 case control studiescase control studies 0.65[0.29; 1.43]4110%NABànhidy (Carbamazepine), 2011 Jentink (Carbamazepine), 2010 2 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.70[0.30; 1.62]-- -NAJentink (Carbamazepine), 2010 1 unexposed, sickunexposed, sick 0.33[0.03; 3.78]411 -NABànhidy (Carbamazepine), 2011 1 Tags Adjustment   - No  - No 0.33[0.03; 3.78]411 -NABànhidy (Carbamazepine), 2011 1   - Yes  - Yes 0.70[0.30; 1.62]-- -NAJentink (Carbamazepine), 2010 1 MatchedMatched 0.33[0.03; 3.78]411 -NABànhidy (Carbamazepine), 2011 1 All studiesAll studies 0.65[0.29; 1.43]4110%NABànhidy (Carbamazepine), 2011 Jentink (Carbamazepine), 2010 20.110.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.26[0.83; 1.90]9,4755,3960%NACohen (Carbamazepine) (Mixed indications) (Controls unexposed, NOS), 2023 Blotière (Carbamazepine) (Controls unexposed NOS) (Mixed indications), 2019 Veiby (Carbamazepine) (Controls unexposed, disease free) (Mixed indications), 2014 Källén (Carbamazepine) (Controls unexposed, NOS) (Indications NOS), 2013 Jentink (Carbamazepine), 2010 D'Souza (Carbamazepine) (Controls unexposed, disease free), 1991 Van der Pol (Carbamazepine) (Controls unexposed, disease free), 1991 7 unexposed, sick controlsunexposed, sick controls 0.76[0.12; 4.89]4250%NABànhidy (Carbamazepine), 2011 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 Van der Pol (Carbamazepine) (Controls unexposed, sick), 1991 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.21[0.69; 2.13]557,3550%NABlotière (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 Tomson (Carbamazepine), 2018 Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014 Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 Källén (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2013 Hernández-Díaz (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2012 60.510.01.0